|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OXLD1 |
Gene summary for OXLD1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OXLD1 | Gene ID | 339229 |
| Gene name | oxidoreductase like domain containing 1 | |
| Gene Alias | C17orf90 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q5BKU9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 339229 | OXLD1 | GSM4909281 | Human | Breast | IDC | 2.65e-05 | 3.24e-01 | 0.21 |
| 339229 | OXLD1 | GSM4909282 | Human | Breast | IDC | 1.65e-02 | 2.54e-01 | -0.0288 |
| 339229 | OXLD1 | GSM4909286 | Human | Breast | IDC | 2.63e-08 | 1.82e-01 | 0.1081 |
| 339229 | OXLD1 | GSM4909289 | Human | Breast | IDC | 1.87e-02 | 4.40e-01 | 0.1064 |
| 339229 | OXLD1 | GSM4909293 | Human | Breast | IDC | 1.55e-07 | 3.20e-01 | 0.1581 |
| 339229 | OXLD1 | GSM4909297 | Human | Breast | IDC | 2.22e-03 | -4.26e-02 | 0.1517 |
| 339229 | OXLD1 | GSM4909298 | Human | Breast | IDC | 1.55e-02 | 1.92e-01 | 0.1551 |
| 339229 | OXLD1 | GSM4909307 | Human | Breast | IDC | 5.32e-03 | 2.97e-01 | 0.1569 |
| 339229 | OXLD1 | GSM4909308 | Human | Breast | IDC | 5.79e-12 | 4.01e-01 | 0.158 |
| 339229 | OXLD1 | GSM4909311 | Human | Breast | IDC | 1.83e-09 | -9.12e-02 | 0.1534 |
| 339229 | OXLD1 | GSM4909317 | Human | Breast | IDC | 1.71e-06 | 3.32e-01 | 0.1355 |
| 339229 | OXLD1 | GSM4909319 | Human | Breast | IDC | 4.06e-23 | 1.79e-01 | 0.1563 |
| 339229 | OXLD1 | GSM4909320 | Human | Breast | IDC | 2.73e-09 | 3.99e-01 | 0.1575 |
| 339229 | OXLD1 | GSM4909321 | Human | Breast | IDC | 3.64e-07 | 1.97e-01 | 0.1559 |
| 339229 | OXLD1 | NCCBC5 | Human | Breast | DCIS | 2.11e-02 | 3.03e-02 | 0.2046 |
| 339229 | OXLD1 | P1 | Human | Breast | IDC | 2.31e-06 | -3.05e-02 | 0.1527 |
| 339229 | OXLD1 | DCIS2 | Human | Breast | DCIS | 9.39e-23 | 4.03e-02 | 0.0085 |
| 339229 | OXLD1 | LZE2T | Human | Esophagus | ESCC | 5.88e-06 | 8.50e-01 | 0.082 |
| 339229 | OXLD1 | LZE4T | Human | Esophagus | ESCC | 5.02e-11 | 3.28e-01 | 0.0811 |
| 339229 | OXLD1 | LZE7T | Human | Esophagus | ESCC | 3.30e-09 | 4.33e-01 | 0.0667 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OXLD1 | SNV | Missense_Mutation | novel | c.236N>T | p.Ser79Leu | p.S79L | Q5BKU9 | protein_coding | deleterious(0.01) | possibly_damaging(0.516) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| OXLD1 | SNV | Missense_Mutation | rs573397609 | c.437G>A | p.Gly146Glu | p.G146E | Q5BKU9 | protein_coding | deleterious(0) | benign(0.006) | TCGA-IR-A3LI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OXLD1 | SNV | Missense_Mutation | novel | c.154G>C | p.Asp52His | p.D52H | Q5BKU9 | protein_coding | deleterious(0.04) | benign(0.005) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| OXLD1 | SNV | Missense_Mutation | c.358G>T | p.Ala120Ser | p.A120S | Q5BKU9 | protein_coding | tolerated(0.07) | probably_damaging(0.991) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| OXLD1 | SNV | Missense_Mutation | novel | c.410N>C | p.Met137Thr | p.M137T | Q5BKU9 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OXLD1 | SNV | Missense_Mutation | novel | c.292N>C | p.Cys98Arg | p.C98R | Q5BKU9 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| OXLD1 | SNV | Missense_Mutation | rs755309317 | c.257N>T | p.Pro86Leu | p.P86L | Q5BKU9 | protein_coding | tolerated(0.11) | benign(0.224) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OXLD1 | SNV | Missense_Mutation | rs772084477 | c.209N>T | p.Ala70Val | p.A70V | Q5BKU9 | protein_coding | tolerated(0.11) | benign(0.003) | TCGA-SL-A6JA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OXLD1 | SNV | Missense_Mutation | novel | c.247N>A | p.Glu83Lys | p.E83K | Q5BKU9 | protein_coding | tolerated(0.34) | benign(0.046) | TCGA-85-A4JB-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | CR |
| OXLD1 | SNV | Missense_Mutation | novel | c.172G>T | p.Gly58Trp | p.G58W | Q5BKU9 | protein_coding | deleterious(0.04) | probably_damaging(0.979) | TCGA-CV-7238-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |